293 related articles for article (PubMed ID: 36016257)
1. The Cellular and Molecular Immunotherapy in Prostate Cancer.
Mukherjee AG; Wanjari UR; Prabakaran DS; Ganesan R; Renu K; Dey A; Vellingiri B; Kandasamy S; Ramesh T; Gopalakrishnan AV
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016257
[TBL] [Abstract][Full Text] [Related]
2. Past, Current, and Future of Immunotherapies for Prostate Cancer.
Boettcher AN; Usman A; Morgans A; VanderWeele DJ; Sosman J; Wu JD
Front Oncol; 2019; 9():884. PubMed ID: 31572678
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
4. Inmunotherapy in prostate cancer.
Anselmo da Costa I; Stenzl A; Bedke J
Arch Esp Urol; 2019 Mar; 72(2):211-222. PubMed ID: 30855023
[TBL] [Abstract][Full Text] [Related]
5. Contemporaneous and upcoming trends in immunotherapy for prostate cancer: review.
Saleem S; Rashid AB; Shehzadi S; Mumtaz H; Saqib M; Bseiso A; Villasenor AV; Ahmed A; Sonia SN
Ann Med Surg (Lond); 2023 Aug; 85(8):4005-4014. PubMed ID: 37554896
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances.
Movassaghi M; Chung R; Anderson CB; Stein M; Saenger Y; Faiena I
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638243
[TBL] [Abstract][Full Text] [Related]
7. Progression in immunotherapy for advanced prostate cancer.
Liang H; Liu Y; Guo J; Dou M; Zhang X; Hu L; Chen J
Front Oncol; 2023; 13():1126752. PubMed ID: 36925917
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Bansal D; Reimers MA; Knoche EM; Pachynski RK
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
[TBL] [Abstract][Full Text] [Related]
9. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
11. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
13. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE; Rescigno P; Catalano F; Mollica V; Vogl UM; Marandino L; Massari F; Pereira Mestre R; Zanardi E; Signori A; Buti S; Bauckneht M; Gillessen S; Banna GL; Fornarini G
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267553
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
18. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
19. Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.
Mukherjee AG; Wanjari UR; Namachivayam A; Murali R; Prabakaran DS; Ganesan R; Renu K; Dey A; Vellingiri B; Ramanathan G; Doss C GP; Gopalakrishnan AV
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146572
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
